ISPOR - First-Line Pembrolizumab in PD-L1 Positive Non-Small Cell Lung Cancer- A Cost-Effectiveness Analysis from A UK Healthcare Perspective

Full Text

First-Line Pembrolizumab in PD-L1 Positive Non-Small Cell Lung Cancer- A Cost-Effectiveness Analysis from A UK Healthcare Perspective

Abstract

Authors

X Hu DP Goldman

Back to Volume 20, Issue 9

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now